The development of combination immunotherapy based on the mediation of regulatory
mechanisms of the tumor immune microenvironment (TIME) is promising. However, a deep …

Non-small cell lung cancer (NSCLC) is the leading cause of death by cancer worldwide.
Despite developments in therapeutic approaches for the past few decades, the 5-year …

Neoantigens arising from mutations in tumor DNA provide targets for immune-based
therapy. Here, we report the clinical and immune data from a Phase Ib clinical trial of a …

Macrophages are critical regulators of tissue homeostasis but are also abundant in the
tumor microenvironment (TME). In both primary tumors and metastases, such tumor …

Idiopathic pulmonary fibrosis (IPF) is a highly heterogeneous, unpredictable and ultimately
lethal chronic lung disease. Over the last decade, two anti-fibrotic agents have been shown …

At present, radiotherapy (RT) still acquires limited success in clinical due to the lessened
DNA damage under hypoxia and acquired immune tolerance owing to the amplified …

Although CRISPR-mediated genome editing holds promise for cancer therapy, inadequate
tumor targeting and potential off-target side effects hamper its outcomes. In this study, we …

Background Extensive research has established the significant correlations between cancer-
associated fibroblasts (CAFs) and various stages of cancer development, including initiation …

As a main subtype of lung cancer, the current situation of non-small cell lung cancer
(NSCLC) remains severe worldwide with a 19% survival rate at 5 years. As the conventional …

The success of personalized medicine in oncology relies on using highly effective and
precise therapeutic modalities such as small interfering RNA (siRNA) and monoclonal …